VALEANT PHARMACEUTICALS INTL
VRX
VRX was delisted on the 27th of September, 2010.
3 hedge funds and large institutions have $1.05M invested in VALEANT PHARMACEUTICALS INTL in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
22% less capital invested
Capital invested by funds: $1.36M → $1.05M (-$302K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Cullinan Associates
Louisville,
Kentucky
|
+$15.9K |
Top Sellers
VRX Hedge Fund Activity: Q1 2018 in Review
3 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in VALEANT PHARMACEUTICALS INTL (VRX) for Q1 2018, worth a combined $1.05M — down 22% from $1.36M a quarter earlier.
Fund positioning in VRX was balanced in Q1 2018: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Cullinan Associates, adding an estimated $15.9K.
- 3 institutional investors held VALEANT PHARMACEUTICALS INTL (VRX) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $1.05M of VALEANT PHARMACEUTICALS INTL stock for Q1 2018, down 22% quarter-over-quarter.
- 0 funds opened new VALEANT PHARMACEUTICALS INTL positions in Q1 2018 and 0 closed out.
- The largest VALEANT PHARMACEUTICALS INTL buyer in Q1 2018 was Cullinan Associates, an estimated $15.9K added.
Based on aggregated 13F filings for Q1 2018.